Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

3.0%

1 terminated/withdrawn out of 33 trials

Success Rate

96.9%

+10.4% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

45%

14 of 31 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 1

18(56.3%)

Phase 2

10(31.3%)

Early Phase 1

2(6.3%)

N/A

1(3.1%)

Phase 4

1(3.1%)

32Total

Phase 1(18)

Phase 2(10)

Early Phase 1(2)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT02375698Phase 1Completed

A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB

Role: lead

NCT01865487Phase 1Completed

A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)

Role: lead

NCT01755598Phase 2Completed

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

Role: collaborator

NCT02378207Phase 1Completed

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

Role: lead

NCT02075203Phase 2Completed

Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents

Role: lead

NCT03175380Early Phase 1Completed

Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US

Role: lead

NCT01967134Phase 1Completed

Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis

Role: lead

NCT01098474Phase 2Completed

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

Role: collaborator

NCT01669096Phase 2Completed

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

Role: collaborator

NCT00950612Phase 2Completed

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents

Role: collaborator

NCT03265977Phase 2Withdrawn

A Phase II Study of H56:IC31 in Healthy Adolescents

Role: lead

NCT01861730Phase 1Completed

Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants

Role: lead

NCT01927159Phase 1Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Role: collaborator

NCT01599897Phase 1Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Role: collaborator

NCT01198366Phase 1Completed

Study of AERAS-402 in Healthy Infants

Role: lead

NCT02097095Completed

Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)

Role: lead

NCT02420444Phase 1Completed

A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults

Role: lead

NCT01017536Phase 2Completed

Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

Role: lead

NCT02063555Phase 1Completed

Phase I Trial of DAR-901

Role: collaborator

NCT00953927Phase 2Completed

A Study of MVA85A in Healthy Infants

Role: lead